Results 51 to 60 of about 1,216 (154)

EPR Characterisation of Phthalocyanine Radical Anions in Near‐Infrared Photocleavage of the Hydrophilic Axial Ligand of a Photoimmunotherapeutic Reagent, IR700 [PDF]

ChemPhotoChem, 2021
AbstractPhotoimmunotherapy (PIT) is a novel cancer therapy that utilises tumour‐specific monoclonal antibodies coupled with a silicon phthalocyanine derivative with biaxial ligands (IR700). Near‐infrared (NIR)‐induced cleavage of these axial ligands induces the aggregation of IR700 on the cell membrane, resulting in cell death.
Osamu Inanami, Wakako Hiraoka, Yuto Goto, Hideo Takakura, Mikako Ogawa   +4 more
openaire   +1 more source

Near infrared photoimmunotherapy targeting DLL3 for small cell lung cancer

EBioMedicine, 2020
Background: Small cell lung cancer (SCLC) has a poor prognosis, and its treatment options are limited. Delta-like protein 3 (DLL3) is expressed specifically in SCLC and is considered a promising therapeutic target for patients with this disease ...
Yoshitaka Isobe, Kazuhide Sato, Yuko Nishinaga, Kazuomi Takahashi, Shunichi Taki, Hirotoshi Yasui, Misae Shimizu, Rena Endo, Chiaki Koike, Noriko Kuramoto, Hiroshi Yukawa, Shota Nakamura, Takayuki Fukui, Koji Kawaguchi, Toyofumi F. Chen-Yoshikawa, Yoshinobu Baba, Yoshinori Hasegawa   +16 more
doaj   +1 more source

Disialoganglioside GD2-Targeted Near-Infrared Photoimmunotherapy (NIR-PIT) in Tumors of Neuroectodermal Origin

Pharmaceutics, 2022
Disialoganglioside (GD2) is a subtype of glycolipids that is highly expressed in tumors of neuroectodermal origins, such as neuroblastoma and osteosarcoma.
Fuyuki F. Inagaki, Takuya Kato, Aki Furusawa, Ryuhei Okada, Hiroaki Wakiyama, Hideyuki Furumoto, Shuhei Okuyama, Peter L. Choyke, Hisataka Kobayashi   +8 more
doaj   +1 more source

Near-infrared photoimmunotherapy targeting GPR87: Development of a humanised anti-GPR87 mAb and therapeutic efficacy on a lung cancer mouse model

EBioMedicine, 2021
Background: GPR87 is a G-protein receptor that is specifically expressed in tumour cells, such as lung cancer, and rarely expressed in normal cells. GPR87 is a promising target for cancer therapy, but its ligand is controversial.
Hirotoshi Yasui, Yuko Nishinaga, Shunichi Taki, Kazuomi Takahashi, Yoshitaka Isobe, Misae Shimizu, Chiaki Koike, Tetsuro Taki, Aya Sakamoto, Keiko Katsumi, Keisuke Ishii, Kazuhide Sato   +11 more
doaj   +1 more source

Abstract 480: Molecular mechanism of action of photoimmunotherapy with antibody-IR700 dye conjugates

Cancer Research, 2020
Abstract INTRODUCTION: Cancer cell-targeted photoimmunotherapy (PIT) is a platform technology under development for the treatment of various cancers. PIT is a drug and device combination that utilizes an antibody conjugated to the IR700 (IRDye 700DX®) light-excitable dye, which upon antigen binding and illumination with non-thermal red ...
Roger Heim, Lew Makings, Torsten Wiemann, Anthony Manibusan, Miguel Garcia-Guzman   +4 more
openaire   +1 more source

Near‐infrared‐induced drug release from antibody–drug double conjugates exerts a cytotoxic photo‐bystander effect

Bioengineering & Translational Medicine, 2022
Ideal cancer treatments specifically target and eradicate tumor cells without affecting healthy cells. Therefore, antibody‐based therapies that specifically target cancer antigens can be considered ideal cancer therapies.
Kazuomi Takahashi, Hirotoshi Yasui, Shunichi Taki, Misae Shimizu, Chiaki Koike, Kentaro Taki, Hiroshi Yukawa, Yoshinobu Baba, Hisataka Kobayashi, Kazuhide Sato   +9 more
doaj   +1 more source

Photoimmunotherapy targeting biliary‐pancreatic cancer with humanized anti‐TROP2 antibody

Cancer Medicine, 2019
Photoimmunotherapy (PIT) is a new type of tumor‐specific treatment utilizing monoclonal antibody (mAb)‐photosensitizer conjugates and near‐infrared (NIR) light irradiation. One potential PIT target, the type I transmembrane protein TROP2, is expressed at
Takashi Nishimura, Makoto Mitsunaga, Ryoichi Sawada, Masayuki Saruta, Hisataka Kobayashi, Noriko Matsumoto, Toru Kanke, Hiroyuki Yanai, Koji Nakamura   +8 more
doaj   +1 more source

Near infrared photoimmunotherapy for cancers: A translational perspective

EBioMedicine, 2021
Near-infrared photoimmunotherapy (NIR-PIT) is a newly-developed, highly-selective cancer treatment, which utilizes a monoclonal antibody conjugated to a photoabsorbing dye, IRDye700DX (IR700).
Yasuhiro Maruoka, Hiroaki Wakiyama, Peter L. Choyke, Hisataka Kobayashi   +3 more
doaj   +1 more source

Phototheranostics of Splenic Myeloid-Derived Suppressor Cells and Its Impact on Spleen Metabolism in Tumor-Bearing Mice

, 2022
SIMPLE SUMMARY: Myeloid-derived suppressor cells (MDSCs) create an immune suppressive tumor microenvironment making them an important target in cancer. Here we demonstrated, in proof-of-principle studies, the ability of near-infrared photoimmunotherapy ...
James D. Barnett, Zaver M. Bhujwalla, Bhujwalla, Zaver M., Jiefu Jin, Kobayashi, Hisataka, Marie-France Penet, Barnett, James D., Jin, Jiefu, Hisataka Kobayashi, Penet, Marie-France   +9 more
core   +1 more source

Targeted Phototherapy for Malignant Pleural Mesothelioma: Near-Infrared Photoimmunotherapy Targeting Podoplanin

Cells, 2020
Malignant pleural mesothelioma (MPM) has extremely limited treatment despite a poor prognosis. Moreover, molecular targeted therapy for MPM has not yet been implemented; thus, a new targeted therapy is highly desirable.
Yuko Nishinaga, Kazuhide Sato, Hirotoshi Yasui, Shunichi Taki, Kazuomi Takahashi, Misae Shimizu, Rena Endo, Chiaki Koike, Noriko Kuramoto, Shota Nakamura, Takayuki Fukui, Hiroshi Yukawa, Yoshinobu Baba, Mika K. Kaneko, Toyofumi F. Chen-Yoshikawa, Hisataka Kobayashi, Yukinari Kato, Yoshinori Hasegawa   +17 more
doaj   +1 more source